KRAS biomarker testing disparities in colorectal cancer patients in New Mexico

Alissa Greenbaum, Charles Wiggins, Angela LW Meisner, Manuel Rojo, Anita Kinney, Ashwani Rajput

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status. Methods The New Mexico Tumor Registry (NMTR), a population-based cancer registry participating in the National Cancer Institute's Surveillance, Epidemiology and End Results program, was queried to identify all incident cases of CRC diagnosed among New Mexico residents from 2010 to 2013. Results Six hundred thirty-seven patients were diagnosed with mCRC from 2010–2013. As expected, KRAS testing in Stage 4 patients presented the highest frequency (38.4%), though testing in stage 3 (8.5%), stage 2 (3.4%) and stage 1 (1.2%) was also observed. In those with metastatic disease, younger patients (≤ 64 years) were more likely to have had testing than patients 65 years and older (p < 0.0001). Patients residing in urban areas received KRAS testing more often than patients living in rural areas (p = 0.019). No significant racial/ethnic disparities were observed (p = 0.66). No significant differences were seen by year of testing. Conclusion Age and geographic disparities exist in the rates of KRAS testing, while sex, race/ethnicity and the year tested were not significantly associated with testing. Further study is required to assess the reasons for these disparities and continued suboptimal adherence to current ASCO KRAS testing guidelines.

Original languageEnglish (US)
Article numbere00448
JournalHeliyon
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Colorectal Neoplasms
Biomarkers
Registries
SEER Program
Guidelines
Medical Oncology
National Cancer Institute (U.S.)
Neoplasms
Monoclonal Antibodies
Population

All Science Journal Classification (ASJC) codes

  • General

Keywords

  • Clinical genetics
  • Health sciences
  • Oncology

Cite this

Greenbaum, A., Wiggins, C., Meisner, A. LW., Rojo, M., Kinney, A., & Rajput, A. (2017). KRAS biomarker testing disparities in colorectal cancer patients in New Mexico. Heliyon, 3(11), [e00448]. https://doi.org/10.1016/j.heliyon.2017.e00448
Greenbaum, Alissa ; Wiggins, Charles ; Meisner, Angela LW ; Rojo, Manuel ; Kinney, Anita ; Rajput, Ashwani. / KRAS biomarker testing disparities in colorectal cancer patients in New Mexico. In: Heliyon. 2017 ; Vol. 3, No. 11.
@article{2f797a10411d45b5b47b539b066dccd9,
title = "KRAS biomarker testing disparities in colorectal cancer patients in New Mexico",
abstract = "Introduction American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status. Methods The New Mexico Tumor Registry (NMTR), a population-based cancer registry participating in the National Cancer Institute's Surveillance, Epidemiology and End Results program, was queried to identify all incident cases of CRC diagnosed among New Mexico residents from 2010 to 2013. Results Six hundred thirty-seven patients were diagnosed with mCRC from 2010–2013. As expected, KRAS testing in Stage 4 patients presented the highest frequency (38.4{\%}), though testing in stage 3 (8.5{\%}), stage 2 (3.4{\%}) and stage 1 (1.2{\%}) was also observed. In those with metastatic disease, younger patients (≤ 64 years) were more likely to have had testing than patients 65 years and older (p < 0.0001). Patients residing in urban areas received KRAS testing more often than patients living in rural areas (p = 0.019). No significant racial/ethnic disparities were observed (p = 0.66). No significant differences were seen by year of testing. Conclusion Age and geographic disparities exist in the rates of KRAS testing, while sex, race/ethnicity and the year tested were not significantly associated with testing. Further study is required to assess the reasons for these disparities and continued suboptimal adherence to current ASCO KRAS testing guidelines.",
keywords = "Clinical genetics, Health sciences, Oncology",
author = "Alissa Greenbaum and Charles Wiggins and Meisner, {Angela LW} and Manuel Rojo and Anita Kinney and Ashwani Rajput",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.heliyon.2017.e00448",
language = "English (US)",
volume = "3",
journal = "Heliyon",
issn = "2405-8440",
publisher = "Elsevier BV",
number = "11",

}

Greenbaum, A, Wiggins, C, Meisner, ALW, Rojo, M, Kinney, A & Rajput, A 2017, 'KRAS biomarker testing disparities in colorectal cancer patients in New Mexico', Heliyon, vol. 3, no. 11, e00448. https://doi.org/10.1016/j.heliyon.2017.e00448

KRAS biomarker testing disparities in colorectal cancer patients in New Mexico. / Greenbaum, Alissa; Wiggins, Charles; Meisner, Angela LW; Rojo, Manuel; Kinney, Anita; Rajput, Ashwani.

In: Heliyon, Vol. 3, No. 11, e00448, 01.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - KRAS biomarker testing disparities in colorectal cancer patients in New Mexico

AU - Greenbaum, Alissa

AU - Wiggins, Charles

AU - Meisner, Angela LW

AU - Rojo, Manuel

AU - Kinney, Anita

AU - Rajput, Ashwani

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Introduction American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status. Methods The New Mexico Tumor Registry (NMTR), a population-based cancer registry participating in the National Cancer Institute's Surveillance, Epidemiology and End Results program, was queried to identify all incident cases of CRC diagnosed among New Mexico residents from 2010 to 2013. Results Six hundred thirty-seven patients were diagnosed with mCRC from 2010–2013. As expected, KRAS testing in Stage 4 patients presented the highest frequency (38.4%), though testing in stage 3 (8.5%), stage 2 (3.4%) and stage 1 (1.2%) was also observed. In those with metastatic disease, younger patients (≤ 64 years) were more likely to have had testing than patients 65 years and older (p < 0.0001). Patients residing in urban areas received KRAS testing more often than patients living in rural areas (p = 0.019). No significant racial/ethnic disparities were observed (p = 0.66). No significant differences were seen by year of testing. Conclusion Age and geographic disparities exist in the rates of KRAS testing, while sex, race/ethnicity and the year tested were not significantly associated with testing. Further study is required to assess the reasons for these disparities and continued suboptimal adherence to current ASCO KRAS testing guidelines.

AB - Introduction American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status. Methods The New Mexico Tumor Registry (NMTR), a population-based cancer registry participating in the National Cancer Institute's Surveillance, Epidemiology and End Results program, was queried to identify all incident cases of CRC diagnosed among New Mexico residents from 2010 to 2013. Results Six hundred thirty-seven patients were diagnosed with mCRC from 2010–2013. As expected, KRAS testing in Stage 4 patients presented the highest frequency (38.4%), though testing in stage 3 (8.5%), stage 2 (3.4%) and stage 1 (1.2%) was also observed. In those with metastatic disease, younger patients (≤ 64 years) were more likely to have had testing than patients 65 years and older (p < 0.0001). Patients residing in urban areas received KRAS testing more often than patients living in rural areas (p = 0.019). No significant racial/ethnic disparities were observed (p = 0.66). No significant differences were seen by year of testing. Conclusion Age and geographic disparities exist in the rates of KRAS testing, while sex, race/ethnicity and the year tested were not significantly associated with testing. Further study is required to assess the reasons for these disparities and continued suboptimal adherence to current ASCO KRAS testing guidelines.

KW - Clinical genetics

KW - Health sciences

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=85034593556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034593556&partnerID=8YFLogxK

U2 - 10.1016/j.heliyon.2017.e00448

DO - 10.1016/j.heliyon.2017.e00448

M3 - Article

AN - SCOPUS:85034593556

VL - 3

JO - Heliyon

JF - Heliyon

SN - 2405-8440

IS - 11

M1 - e00448

ER -